Bitcoin price today: dips below $112k, near 6-wk low despite Fed cut bets
In a recent transaction, Alaleh Nouri, Executive Vice President, Chief Legal Officer, and Corporate Secretary of PROCEPT BioRobotics Corp (NASDAQ:PRCT), sold 316 shares of the company’s common stock. According to InvestingPro data, the company’s stock has declined approximately 31% over the past six months, though it maintains a strong liquidity position with current assets significantly exceeding short-term obligations. The shares were sold at a weighted average price of $57.06 each, totaling $18,030. This sale was executed on March 18, 2025, to cover tax withholding obligations related to the vesting of Restricted Stock Units. Following this transaction, Nouri holds 61,473 shares directly. The company currently trades at a Price/Book ratio of 7.9x, with analysts maintaining coverage of the stock. For comprehensive analysis and additional insights, access the detailed Pro Research Report available on InvestingPro.
In other recent news, Procept BioRobotics Corp reported its fourth-quarter 2024 earnings, with revenue reaching $68.24 million, surpassing the forecast of $66.83 million. However, the company posted an earnings per share (EPS) of -$0.35, slightly missing the expected -$0.34. For the full year 2024, the company achieved a 65% year-over-year increase in revenue, totaling $224.5 million. Looking ahead, Procept BioRobotics anticipates a 43% revenue growth in 2025, with projections of $320 million in total revenue for the year.
Jefferies recently maintained its Hold rating on Procept BioRobotics with a price target of $77.00, following discussions with company executives. The firm noted the company’s positive outlook on market positioning and growth prospects, particularly in the treatment of benign prostatic hyperplasia (BPH) and prostate cancer. The company is also focusing on expanding its installed base and increasing procedure volumes, with expectations of maintaining a gross margin of 64.5% in 2025. Additionally, Procept BioRobotics is optimistic about its Hydros robotic system, which has been a significant driver of growth alongside new product launches and FDA clearances.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.